| heal.abstract |
Psychiatric disorders represent a major global health challenge, associated with high disability, comorbidities, and premature mortality. Pharmacological treatment in psychiatry is complicated by drug–laboratory test interactions (DLTIs), which can obscure diagnosis, delay therapy, and compromise patient safety. Existing DLTI databases and rule-based clinical decision support systems often lack longitudinal insight and fail to capture patient heterogeneity. This thesis investigates whether deep learning–based representation learning can improve DLTI detection and provide explainable patient stratification in psychiatric care. A retrospective longitudinal cohort study was conducted using electronic health records from 248 inpatients of the 1st Department of Psychiatry, Eginition University Hospital, Athens (2020–2024). Demographic, clinical, laboratory, and pharmacological data (n = 1,490 observations) were extracted and standardized (ICD-10, ATC, LOINC). A masked autoencoder was developed in PyTorch to generate latent embeddings of patient trajectories, followed by k-means clustering (k = 3). Cluster explainability was assessed using an overfitted XGBoost classifier with SHAP interpretation. Linear Mixed Effects (LME) models were then applied to examine the association between psychotropic medications and laboratory biomarkers, adjusting for confounders and intra-patient variability. The masked autoencoder achieved stable training dynamics and generated compact, well-separated clusters (Silhouette = 0.83, Davies–Bouldin = 0.09). SHAP analysis identified gender, psychiatric diagnoses (F20–F32), age, and hospitalization frequency as the primary drivers of cluster assignment. Distinct DLTI patterns emerged across subgroups. Overall, the majority of significant DLTIs were observed within antipsychotic, antidepressant, and anxiolytic classes, predominantly affecting hematological and hepatic biomarkers such as eosinophils, bilirubin, and inflammatory markers. Distinct patterns were observed across patient clusters, reflecting underlying phenotypic and pharmacological variability. Several of these findings align with known DLTIs, while others highlight potentially novel associations warranting further investigation. This study demonstrates that masked autoencoders combined with clustering and explainability methods can uncover clinically meaningful patient subtypes and reveal drug–laboratory interactions in psychiatric populations. By integrating longitudinal EHR data with interpretable deep learning, this framework provides a scalable approach for DLTI detection and personalized monitoring. Although external validation is required, the findings underscore the promise of AI-enhanced laboratory information systems in supporting psychiatric decision making and improving patient safety. |
en |